Clinical trial
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine…
NCT00126867 · AHS Cancer Control Alberta, Other · Terminated
Key facts
| NCT number | NCT00126867 |
|---|---|
| Title | Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Chemotherapy in Colon Cancer Treatment |
| Official title | Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Based Adjuvant Chemotherapy in Colon Cancer Treatment |
| Lead sponsor | AHS Cancer Control Alberta, Other |
| Status | Terminated |
| Study type | Observational |
| Conditions | Colon Cancer |
| Enrollment | 29 |
| Start date | May 1, 2005 |
| Primary completion | Apr 11, 2019 |
| Completion | Apr 11, 2019 |
| First posted | Aug 5, 2005 |
| Last update posted | Jul 5, 2019 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: